Author

C. Janneke van der Woude

Pregnancy in IBD
Pregnancy in IBD

C. Janneke van der Woude  et al.

The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease
The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease

C. Janneke van der Woude  et al.

Mistakes in inflammatory bowel disease and reproduction and how to avoid them
Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude  et al.

Mistakes in pregnancy and IBD
Mistakes in pregnancy and IBD

C. Janneke van der Woude

PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY
PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY

C. Janneke van der Woude  et al.

CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL
CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL

C. Janneke van der Woude  et al.

ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL
ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL

C. Janneke van der Woude  et al.

PREGNANCY OUTCOMES IN THE OZANIMOD CLINICAL DEVELOPMENT PROGRAM IN ULCERATIVE COLITIS, CROHN’S DISEASE, AND RELAPSING MULTIPLE SCLEROSIS
PREGNANCY OUTCOMES IN THE OZANIMOD CLINICAL DEVELOPMENT PROGRAM IN ULCERATIVE COLITIS, CROHN’S DISEASE, AND RELAPSING MULTIPLE SCLEROSIS

C. Janneke van der Woude  et al.

DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE

C. Janneke van der Woude  et al.

PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?
PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?

C. Janneke van der Woude  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

C. Janneke van der Woude  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

C. Janneke van der Woude  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

C. Janneke van der Woude  et al.

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

C. Janneke van der Woude  et al.

Item 1 - 14 / 14
1